Systemic Therapy Options for Patients With Metastatic Endometrial Cancer
Comprehensive insight to the systemic treatment armamentarium available to patients with metastatic EC.
Transcript:
Bhavana Pothuri, MD: In terms of, “would I have added on brachytherapy to external beam,” I probably would've included vaginal brachytherapy as well. Something else that I would've considered is if this was a endometrial cancer that was confined to the endometrium without any myoinvasion, I would actually consider hormonal therapy in someone who was refusing surgical treatment.
At the present time, I think the standard of care still remains paclitaxel and carboplatin. This is what I would start with. The one thing I would consider is adding immunotherapy after a few cycles, given that her tumor is dMMR [mismatch repair deficient]. Hopefully we will have data from the ongoing studies, RUBY, DUO-E, and NRG-GY018, which will help us move immunotherapy into an earlier line of treatment.
There are currently 2 that are approved for this indication of dMMR endometrial cancer, pembrolizumab as well as dostarlimab. Both are PD-1 [programmed cell death protein 1] inhibitors that bind to PD-1 and block PD-1 and PD-L1 [programmed death-ligand] or PD-L2, and essentially restore the cytotoxic activity of T-cells and the immune system to fight cancer. There are other PD-1 inhibitors as well as PD-L1 inhibitors that have been studied in trials, but these are the 2 that are currently FDA approved and available for use as treatment in our patients.
Transcript edited for clarity.
Lenvatinib-Pembrolizumab Duo Delivers Impressive Results in Endometrial Cancer
September 18th 2024The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy.
Read More
